MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge University, Cambridge, UK.
Lancet. 2013 Oct 26;382(9902):1405-12. doi: 10.1016/S0140-6736(13)61570-6. Epub 2013 Jul 17.
BACKGROUND: The prevalence of dementia is of interest worldwide. Contemporary estimates are needed to plan for future care provision, but much evidence is decades old. We aimed to investigate whether the prevalence of dementia had changed in the past two decades by repeating the same approach and diagnostic methods as used in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) in three of the original study areas in England. METHODS: Between 1989 and 1994, MRC CFAS investigators did baseline interviews in populations aged 65 years and older in six geographically defined areas in England and Wales. A two stage process, with screening followed by diagnostic assessment, was used to obtain data for algorithmic diagnoses (geriatric mental state-automated geriatric examination for computer assisted taxonomy), which were then used to estimate dementia prevalence. Data from three of these areas--Cambridgeshire, Newcastle, and Nottingham--were selected for CFAS I. Between 2008 and 2011, new fieldwork was done in the same three areas for the CFAS II study. For both CFAS I and II, each area needed to include 2500 individuals aged 65 years and older to provide power for geographical and generational comparison. Sampling was stratified according to age group (65-74 years vs ≥75 years). CFAS II used identical sampling, approach, and diagnostic methods to CFAS I, except that screening and assessement were combined into one stage. Prevalence estimates were calculated using inverse probability weighting methods to adjust for sampling design and non-response. Full likelihood Bayesian models were used to investigate informative non-response. FINDINGS: 7635 people aged 65 years or older were interviewed in CFAS I (9602 approached, 80% response) in Cambridgeshire, Newcastle, and Nottingham, with 1457 being diagnostically assessed. In the same geographical areas, the CFAS II investigators interviewed 7796 individuals (14,242 approached, 242 with limited frailty information, 56% response). Using CFAS I age and sex specific estimates of prevalence in individuals aged 65 years or older, standardised to the 2011 population, 8·3% (884,000) of this population would be expected to have dementia in 2011. However, CFAS II shows that the prevalence is lower (6·5%; 670,000), a decrease of 1·8% (odds ratio for CFAS II vs CFAS I 0·7, 95% CI 0·6-0·9, p=0·003). Sensitivity analyses suggest that these estimates are robust to the change in response. INTERPRETATION: This study provides further evidence that a cohort effect exists in dementia prevalence. Later-born populations have a lower risk of prevalent dementia than those born earlier in the past century. FUNDING: UK Medical Research Council.
背景:痴呆症的患病率是全世界都关注的问题。为了规划未来的护理服务,需要进行当代的估计,但许多证据都已经有几十年的历史了。我们的目的是通过在英格兰的三个原始研究区域重复使用与医学研究委员会认知功能和衰老研究(MRC CFAS)相同的方法和诊断方法,来调查过去二十年中痴呆症的患病率是否发生了变化。
方法:1989 年至 1994 年,MRC CFAS 研究人员在英格兰和威尔士的六个地理定义区域中对 65 岁及以上的人群进行了基线访谈。采用两步法,先进行筛查,然后进行诊断评估,以获取算法诊断的数据(老年精神状态-计算机辅助分类的自动老年检查),然后用于估计痴呆症的患病率。从这三个地区(剑桥郡、纽卡斯尔和诺丁汉)中选择了三个地区进行 CFAS I。在 2008 年至 2011 年期间,在相同的三个地区进行了 CFAS II 研究的新实地工作。对于 CFAS I 和 II,每个地区都需要包括 2500 名 65 岁及以上的人,以提供地理和代际比较的能力。根据年龄组(65-74 岁与≥75 岁)进行分层抽样。CFAS II 使用与 CFAS I 相同的采样、方法和诊断方法,只是将筛查和评估合并为一个阶段。使用逆概率加权方法来调整采样设计和无应答的影响,以计算患病率估计值。使用全似然贝叶斯模型来调查信息性无应答情况。
结果:在 CFAS I 中,共有 7635 名 65 岁及以上的人接受了采访(Cambridgeshire、Newcastle 和 Nottingham 共 9602 人被邀请,应答率为 80%),其中 1457 人进行了诊断评估。在相同的地理区域,CFAS II 研究人员采访了 7796 人(14242 人被邀请,242 人有有限的脆弱性信息,应答率为 56%)。使用 CFAS I 中年龄和性别特异性的患病率估计值,以 2011 年的人口为标准,预计该人群中有 8.3%(884000 人)在 2011 年患有痴呆症。然而,CFAS II 表明患病率较低(6.5%;670000 人),下降了 1.8%(CFAS II 与 CFAS I 的比值比为 0.7,95%CI 0.6-0.9,p=0.003)。敏感性分析表明,这些估计值对反应变化具有稳健性。
解释:这项研究进一步证明了痴呆症患病率存在队列效应。与上个世纪出生的人相比,后来出生的人群患常见性痴呆症的风险较低。
资金:英国医学研究理事会。
Eur J Epidemiol. 2019-9-5
Br J Psychiatry. 2020-1
Demography. 2025-8-1
Alzheimers Dement. 2025-7
Neuroscience. 2025-8-30
Front Nutr. 2025-7-9
BMJ Public Health. 2025-6-25
Front Neurol. 2025-5-27
Alzheimers Dement. 2013-1
Alzheimers Dement. 2013-1